[1]
|
曹毛毛, 陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床, 2019, 46(3): 145-149.
|
[2]
|
Miller, K.D., Siegel, R.L., Lin, C.C., et al. (2016) Cancer Treatment and Survivorship Statistics, 2016. CA: A Cancer Journal for Cli-nicians, 66, 271-289. https://doi.org/10.3322/caac.21349
|
[3]
|
Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654
|
[4]
|
Kris, M.G., Johnson, B.E., Berry, L.D., et al. (2014) Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA, 311, 1998-2006. https://doi.org/10.1001/jama.2014.3741
|
[5]
|
Papadimitrakopoulou, V.A., Mok, T.S., Han, J.Y., et al. (2020) Osi-mertinib versus Platinum-Pemetrexed for Patients with EGFR T790M Advanced NSCLC and Progression on a Prior EGFR-Tyrosine Kinase Inhibitor: AURA3 Overall Survival Analysis. Annals of Oncology, 31, 1536-1544. https://doi.org/10.1016/j.annonc.2020.08.2100
|
[6]
|
姬巧霞, 张红斌, 王愿, 赵敏. 晚期非小细胞肺癌患者表皮生长因子受体基因突变的危险因素及表皮生长因子受体酪氨酸激酶抑制剂的疗效分析[J]. 中国医药, 2023, 18(2): 211-215.
|
[7]
|
Bach, D.H., Kim, D., Bae, S.Y., et al. (2018) Targeting Nicotinamide N-Methyltransferase and miR-449a in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer Cells. Molecular Therapy Nucleic Acids, 11, 455-467.
https://doi.org/10.1016/j.omtn.2018.03.011
|
[8]
|
Mok, T.S., Cheng, Y., Zhou, X., et al. (2018) Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib with Gefitinib in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Journal of Clinical Oncology, 36, 2244-2250. https://doi.org/10.1200/JCO.2018.78.7994
|
[9]
|
Sabbah, D.A., Hajjo, R. and Sweidan, K. (2020) Review on Epi-dermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR In-hibitors. Current Topics in Medicinal Chemistry, 20, 815-834. https://doi.org/10.2174/1568026620666200303123102
|
[10]
|
Ben-Dayan, D., Mittelman, M., Floru, S., et al. (1994) Transverse Nail Ridgings (Beau’s Lines) Induced by Chemotherapy. Acta Haematologica, 91, 89-90. https://doi.org/10.1159/000204261
|
[11]
|
Ermertcan, A.T., Yaşar, A., Kayhan, T., et al. (2011) Hypohidrotic Ecto-dermal Dysplasia Associated with Glucose-6-Phosphate Dehydrogenase Deficiency. Annals of Dermatology, 23, S8-s10.
https://doi.org/10.5021/ad.2011.23.S1.S8
|
[12]
|
Tucker, W.F. and Church, R.E. (1984) Beau’s Lines after Razoxane Therapy for Psoriasis. Archives of Dermatology, 120, 1140. https://doi.org/10.1001/archderm.1984.01650450022008
|
[13]
|
Patki, A.H. and Mehta, J.M. (1989) Dap-sone-Induced Erythroderma with Beau’s Lines. Leprosy Review, 60, 274-277.
https://doi.org/10.5935/0305-7518.19890034
|
[14]
|
Hood, A.F. (1986) Cutaneous Side Effects of Cancer Chemo-therapy. Medical Clinics of North America, 70, 187-209.
https://doi.org/10.1016/S0025-7125(16)30976-2
|
[15]
|
Requena, L. (1991) Chemotherapy-Induced Transverse Ridging of the Nails. Cutis, 48, 129-130.
|